An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi.
Contact Information for Access
- piomanliomirko.frascione@inoc.it
- corrado.benevolosavelli@inoc.it
- carola.maza@inoc.it
- ufficio.trials@inoc.it
Status
ATTIVO
Objective of the study
The purpose of the study is to evaluate the superiority of treatment with obinutuzumab compared to radiation therapy alone.
Follicular lymphoma.
ClinicalTrials.gov ID NCT05929222
Sponsor: Italian Lymphoma Foundation - ETS
Medication
Obinutuzumab + radiation therapy vs. radiation therapy
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients diagnosed with follicular lymphoma.
View the full study Back to search page